|
CA5B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.62960000627788E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.6042999999577E-06 |
| Normal-vs-Stage2 |
3.447600E-04 |
| Normal-vs-Stage3 |
3.92169996477065E-09 |
| Normal-vs-Stage4 |
1.77299952497378E-10 |
| Stage1-vs-Stage2 |
8.509000E-01 |
| Stage1-vs-Stage3 |
3.016400E-02 |
| Stage1-vs-Stage4 |
2.399100E-03 |
| Stage2-vs-Stage3 |
1.733790E-01 |
| Stage2-vs-Stage4 |
1.475650E-02 |
| Stage3-vs-Stage4 |
1.671770E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.89709997395249E-09 |
| Normal-vs-AfricanAmerican |
2.662300E-02 |
| Normal-vs-Asian |
2.098000E-02 |
| Caucasian-vs-AfricanAmerican |
4.324000E-01 |
| Caucasian-vs-Asian |
1.053250E-01 |
| AfricanAmerican-vs-Asian |
7.351800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.35023153453085E-12 |
| Normal-vs-Female |
8.46710000002027E-07 |
| Male-vs-Female |
9.63200000000386E-05 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.20149999999864E-05 |
| Normal-vs-Age(41-60Yrs) |
1.75810000002663E-07 |
| Normal-vs-Age(61-80Yrs) |
4.00850019843801E-10 |
| Normal-vs-Age(81-100Yrs) |
3.981800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.640800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.857400E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.036000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.958200E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.942800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.766600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.90640000452547E-08 |
| Classical-VS-Follicular |
1.426000E-02 |
| Classical-VS-Other |
2.882800E-01 |
| Classical-VS-Normal |
2.34289999999637E-05 |
| Tall-VS-Follicular |
1.201300E-03 |
| Tall-VS-Other |
1.722610E-01 |
| Tall-VS-Normal |
2.87248003161267E-12 |
| Follicular-VS-Other |
5.962800E-01 |
| Follicular-VS-Normal |
1.2285999995143E-08 |
| Other-VS-Normal |
2.281500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.59069999686679E-08 |
| Normal-vs-N1 |
5.37449999948869E-07 |
| N0-vs-N1 |
1.832000E-01 |
|
|
